Table 1.
Characteristics of all patients (n = 177).
| Characteristic | All Patients |
|---|---|
| N | 177 |
| Age (years) | 74 (38–90) |
| Sex (female/male) | 35/142 |
| BMI | 22.5 (15–38.9) |
| Etiology (HBV/HCV/Others) | 34/82/61 |
| Child-Pugh score (5/6) | 135/42 |
| ALBI grade (1/2) | 73/104 |
| AST (U/L) | 37 (13–160) |
| ALT (U/L) | 29 (6–126) |
| Diabetes mellitus (+/-) | (75/102) |
| Maximum tumor diameter (mm) | 32 (10–127) |
| Number of tumors | |
| <5/≥5 | 54/123 |
| BCLC stage (B/C) | 105/72 |
| AFP (ng/mL) | 51.2 (1.0–146,260) |
| DCP (mAU/mL) | 233.5 (3.3–524,068) |
| Prior treatment of MTAs | 41 |
| (SORA/SORA+REGO) | (29/12) |
| Follow-up duration (month) | 12.2 (2.1–29.2) |
Note. Data are expressed as median (range), or number. Abbreviations: BMI, Body Mass Index; HBV, hepatitis B virus; HCV, hepatis C virus; ALBI grade, Albumin-bilirubin grade; AST; aspartate transaminase, ALT; alanine aminotransferase, BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin, MTAs; molecular target drugs, SORA; sorafenib, REGO; regorafenib.